Big Pharma puts $250M towards disease collaboration

Share this article:

Big Pharma is pooling its resources and pitching in a combined $230 million for research efforts to identify biomarkers for diseases including Alzheimer's, type 2 diabetes and rheumatoid arthritis. The project, named the Accelerating Medicines Partnership, is corralled by the National Institutes of Health (NIH) and was two years in the making.

The research collaboration is expected to span between three and five years, and a key component of the effort is that the roster of drug makers—which includes AbbVie, Biogen Idec, GlaxoSmithKline, Merck and Takeda—is that they will share their results with the community at large, a strategy The Wall Street Journal notes is in line with an open-source approach that is used in other fields, but is generally anathema to a field in which healthful discoveries are valued for their scientific potential as well as their profit potential.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.